Abstract: The present invention relates to an injectable composition for extended release of fingolimod comprising a suspension of at least about 0.5 mg/ml of fingolimod, wherein fingolimod release is for at least 7 days and the process for preparation thereof.

Abstract: The present invention relates to the stable liquid pharmaceutical composition comprising (a) cabazitaxel or a pharmaceutically acceptable salt or solvate thereof, (b) one or more solubilizers selected from the group consisting of soya phosphatidyl choline, polyethylene glycol and glycocholic acid, (c) a solvent and (d) a co-solvent, wherein the pharmaceutical composition is substantially free of (i) polysorbates and (ii) stabilizers selected from the group consisting of preservatives, antioxidants and chelating agents and the process for preparation thereof, and the methods of using the stable liquid pharmaceutical composition of cabazitaxel for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel containing treatment regimen.